Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of...
– Company also receives short extension of its credit agreement until July 31, 2024 –MINNEAPOLIS, June 17, 2024 (GLOBE NEWSWIRE)...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the UK and...
Company to share groundbreaking technology at the AgeTech Collaborative from AARP as part of their launch. BROOKLYN, N.Y., June 10,...
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma...
BIRMINGHAM, United Kingdom--(BUSINESS WIRE)--As part of the MedTech Innovation Expo, the leading trade show in the medical device design and...
Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the...
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa,...
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations...
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite...
As federal and state governments implement far-ranging programs to address the crisis, PillSafe offers a technology-based solution that ensures patients...
Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certificationLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”...
Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certificationLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”...
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an...
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4...